TrianglePembrolizumab (NCT06041503)
Pembrolizumab trial for Adenocarcinoma of the Bladder (NCT06041503). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged 18–120 with locally advanced or metastatic pure urinary-tract adenocarcinoma or squamous-cell carcinoma, or treatment-refractory testicular germ-cell tumors. Germ-cell disease must have exhausted standard treatments intended to eliminate cancer.
The idea: intravenous enfortumab vedotin delivers a toxic payload to nectin-4-bearing cells. Patients without prior checkpoint immunotherapy can also receive pembrolizumab. The groups use different schedules. Researchers measure tumor response. Tumor tissue is required; biopsy is required if stored tissue is unsuitable.
This phase 2 study plans 68 patients. Andrea Apolo leads in Bethesda, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.